Follow the people · Insider
Derrell Porter
Derrell Porter files insider transactions with the SEC as a director of Acumen Pharmaceuticals (ABOS). We hold 3 disclosed purchases and sales filed since 11 May 2017, 3 of them in the last 90 days.
- Files forABOS
- Disclosed buys and sells3 in all, 3 in the last 90 days
- Last disclosure17 June 2026
Positions held
3 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 4 January 2023 — 17 June 2026Director · Acumen Pharmaceuticals (ABOS)14 Form 4 lines · source: SEC Form 4
- Filed 27 May 2021 — 19 May 2026Director · Passage BIO (PASG)6 Form 4 lines · source: SEC Form 4
- Filed 10 May 2017 — 26 March 2019SVP, Head of Global Commercial · Atara Biotherapeutics (ATRA)14 Form 4 lines · source: SEC Form 4
Everything they disclosed
34 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 6,460 shares of Acumen PharmaceuticalsSEC Form 417 June 2026Common Stock · traded 15 June 2026 · filed 17 June 2026
- ▼ sold on the open market 6,460 shares of Acumen PharmaceuticalsSEC Form 417 June 2026Common Stock · traded 15 June 2026 · filed 17 June 2026
- ▼ sold on the open market 12,800 shares of Acumen PharmaceuticalsSEC Form 417 June 2026Common Stock · traded 16 June 2026 · filed 17 June 2026
- exercised options over 13,040 shares of Acumen PharmaceuticalsSEC Form 417 June 2026Common Stock · traded 17 June 2026 · filed 17 June 2026
- ▼ sold on the open market 13,040 shares of Acumen PharmaceuticalsSEC Form 417 June 2026Common Stock · traded 17 June 2026 · filed 17 June 2026
- exercised options over 6,460 shares of Acumen Pharmaceuticals (a derivative holding)SEC Form 417 June 2026Stock Option (right to buy) · traded 15 June 2026 · filed 17 June 2026
- exercised options over 13,040 shares of Acumen Pharmaceuticals (a derivative holding)SEC Form 417 June 2026Stock Option (right to buy) · traded 17 June 2026 · filed 17 June 2026
- was granted 35,500 shares of Acumen PharmaceuticalsSEC Form 45 June 2026Common Stock · traded 3 June 2026 · filed 5 June 2026
- was granted 53,250 shares of Acumen Pharmaceuticals (a derivative holding)SEC Form 45 June 2026Stock Option (right to buy) · traded 3 June 2026 · filed 5 June 2026
- was granted 10,539 shares of Passage BIO (a derivative holding)SEC Form 421 May 2026Director Stock Option (right to buy) · traded 19 May 2026 · filed 21 May 2026
- was granted 19,500 shares of Acumen Pharmaceuticals (a derivative holding)SEC Form 45 June 2025Stock Option (right to buy) · traded 4 June 2025 · filed 5 June 2025
- was granted 12,800 shares of Acumen PharmaceuticalsSEC Form 45 June 2025Common Stock · traded 4 June 2025 · filed 5 June 2025
- was granted 201,857 shares of Passage BIO (a derivative holding)SEC Form 430 May 2025Director Stock Option (right to buy) · traded 28 May 2025 · filed 30 May 2025
- was granted 25,000 shares of Acumen Pharmaceuticals (a derivative holding)SEC Form 410 June 2024Stock Option (right to buy) · traded 10 June 2024 · filed 10 June 2024
- was granted 47,693 shares of Passage BIO (a derivative holding)SEC Form 423 May 2024Director Stock Option (right to buy) · traded 21 May 2024 · filed 23 May 2024
- was granted 25,000 shares of Acumen Pharmaceuticals (a derivative holding)SEC Form 47 June 2023Stock Option (right to buy) · traded 6 June 2023 · filed 7 June 2023
- was granted 24,000 shares of Passage BIO (a derivative holding)SEC Form 426 May 2023Director Stock Option (Right to Buy) · traded 25 May 2023 · filed 26 May 2023
- was granted 50,000 shares of Acumen Pharmaceuticals (a derivative holding)SEC Form 44 January 2023Stock Option Grant (right to buy) · traded 4 January 2023 · filed 4 January 2023
- was granted 24,000 shares of Passage BIO (a derivative holding)SEC Form 431 May 2022Director Stock Option (Right to Buy) · traded 26 May 2022 · filed 31 May 2022
- was granted 33,836 shares of Passage BIO (a derivative holding)SEC Form 428 May 2021Director Stock Option (Right to Buy) · traded 27 May 2021 · filed 28 May 2021
- was granted 10,000 shares of Atara BiotherapeuticsSEC Form 427 March 2019Common Stock · traded 26 March 2019 · filed 27 March 2019
- exercised options over 4,000 shares of Atara Biotherapeutics (a derivative holding)SEC Form 419 February 2019Employee Stock Option (Right to Buy) · traded 15 February 2019 · filed 19 February 2019
- exercised options over 4,000 shares of Atara BiotherapeuticsSEC Form 419 February 2019Common Stock · traded 15 February 2019 · filed 19 February 2019
- ▼ sold on the open market 5,909 shares of Atara BiotherapeuticsSEC Form 419 February 2019Common Stock · traded 15 February 2019 · filed 19 February 2019
- was granted 24,625 shares of Atara Biotherapeutics (a derivative holding)SEC Form 48 February 2019Employee Stock Option (Right to Buy) · traded 6 February 2019 · filed 8 February 2019
- had shares withheld for tax on 1,216 shares of Atara BiotherapeuticsSEC Form 48 February 2019Common Stock · traded 6 February 2019 · filed 8 February 2019
- was granted 12,313 shares of Atara BiotherapeuticsSEC Form 48 February 2019Common Stock · traded 6 February 2019 · filed 8 February 2019
- exercised options over 16,334 shares of Atara Biotherapeutics (a derivative holding)SEC Form 416 May 2018Employee Stock Option (Right to Buy) · traded 15 May 2018 · filed 16 May 2018
- exercised options over 16,334 shares of Atara BiotherapeuticsSEC Form 416 May 2018Common Stock · traded 15 May 2018 · filed 16 May 2018
- ▼ sold on the open market 16,334 shares of Atara BiotherapeuticsSEC Form 416 May 2018Common Stock · traded 15 May 2018 · filed 16 May 2018
- ▼ sold on the open market 1,544 shares of Atara BiotherapeuticsSEC Form 48 May 2018Common Stock · traded 8 May 2018 · filed 8 May 2018
- was granted 25,000 shares of Atara Biotherapeutics (a derivative holding)SEC Form 48 February 2018Employee Stock Option (Right to Buy) · traded 6 February 2018 · filed 8 February 2018
- was granted 12,500 shares of Atara BiotherapeuticsSEC Form 48 February 2018Common Stock · traded 6 February 2018 · filed 8 February 2018
- was granted 130,000 shares of Atara Biotherapeutics (a derivative holding)SEC Form 411 May 2017Employee Stock Option (Right to Buy) · traded 10 May 2017 · filed 11 May 2017
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.